Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial

Authors: Michael P. Whyte, Thomas O. Carpenter, Gary S. Gottesman, Meng Mao, Alison Skrinar, Javier San Martín, Erik A. Imel - The Lancet 2019 cited by 182